{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:14:14Z","timestamp":1789827254081,"version":"4.0.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1093\/ejcts\/ezy370","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T15:17:30Z","timestamp":1538752650000},"page":"691-698","source":"Crossref","is-referenced-by-count":18,"title":["Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms"],"prefix":"10.1093","volume":"55","author":[{"given":"Luis F","family":"Tapias","sequence":"first","affiliation":[{"name":"Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Shih","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Mino-Kenudson","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Muniappan","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning A","family":"Gaissert","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lanuti","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J","family":"Mathisen","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald C","family":"Ott","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1053\/j.semtcvs.2009.06.001","article-title":"Treatment of tracheal tumors","volume":"21","author":"Gaissert","year":"2009","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B2","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.athoracsur.2004.05.064","article-title":"Long-term survival after resection of primary adenoid cystic and squamous cell carcinoma of the trachea and carina","volume":"78","author":"Gaissert","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B3","doi-asserted-by":"crossref","first-page":"2212.","DOI":"10.1001\/jama.2018.4653","article-title":"Feasibility of bioengineered tracheal and bronchial reconstruction using stented aortic matrices","volume":"319","author":"Martinod","year":"2018","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B4","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ejcts.2010.01.005","article-title":"Prognostic value of pathologic characteristics and resection margins in tracheal adenoid cystic carcinoma","volume":"37","author":"Honings","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ctrv.2018.02.002","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): approaches on special subgroups and unresolved burning questions","volume":"64","author":"Remon","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B6","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B7","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.athoracsur.2016.08.021","article-title":"Successful treatment of an aggressive tracheal malignancy with immunotherapy","volume":"103","author":"Osho","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B8","volume-title":"IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer","author":"Tsao","year":"2017"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B9","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jtho.2016.08.134","article-title":"Programmed cell death ligand 1 expression in resected lung adenocarcinomas: association with immune microenvironment","volume":"11","author":"Huynh","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B10","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1158\/1078-0432.CCR-14-1905","article-title":"Stromal CD8+ T-cell density\u2014a promising supplement to TNM staging in non-small cell lung cancer","volume":"21","author":"Donnem","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtcvs.2004.07.005","article-title":"Anastomotic complications after tracheal resection: prognostic factors and management","volume":"128","author":"Wright","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0382-2","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)","volume":"6","author":"Brahmer","year":"2018","journal-title":"J Immunother Cancer"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B14","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B15","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B16","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B17","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/107327480601300406","article-title":"Tracheobronchial gland tumors","volume":"13","author":"Gaissert","year":"2006","journal-title":"Cancer Control"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/2326-6066.CIR-16-0031","article-title":"Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes","volume":"4","author":"Sridharan","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jso.24266","article-title":"Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas","volume":"114","author":"Mukaigawa","year":"2016","journal-title":"J Surg Oncol"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4069-3","article-title":"PD-L1 expression in malignant salivary gland tumors","volume":"18","author":"Harada","year":"2018","journal-title":"BMC Cancer"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B22","article-title":"Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study","author":"Cohen","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B23","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B24","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031804570350900_ezy370-B25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/1078-0432.CCR-15-1543","article-title":"Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma","volume":"22","author":"Vassilakopoulou","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Cardio-Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ejcts\/article-pdf\/55\/4\/691\/28072262\/ezy370.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T05:14:02Z","timestamp":1552886042000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejcts\/article\/55\/4\/691\/5173724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,11,12]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ejcts\/ezy370","relation":{},"ISSN":["1010-7940","1873-734X"],"issn-type":[{"value":"1010-7940","type":"print"},{"value":"1873-734X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2018,11,12]]}}}